Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Greenworks
301260
5
Tuoxin Pharmaceutical Group
301089
(Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -34.32%39.84M | -8.42%191.51M | -57.95%13.71M | 105.83%46M | -27.42%71.15M | 8.03%60.65M | -0.67%209.13M | 40.52%32.62M | 1.46%22.35M | 82.23%98.02M |
Net income from continuing operations | 29.51%-11.02M | -137.01%-21.27M | 55.16%-9.51M | -730.54%-8.51M | 31.43%12.38M | -1,176.32%-15.64M | -158.18%-8.97M | -194.36%-21.2M | -69.35%1.35M | 0.67%9.42M |
Operating gains losses | -153.69%-80K | -22.90%1.43M | 14.75%630K | -65.98%281K | 161.54%374K | -56.43%149K | -6.30%1.86M | 33.58%549K | 151.06%826K | -74.78%143K |
Depreciation and amortization | 6.75%2.56M | -5.54%10.29M | -7.18%2.55M | -14.73%2.38M | 6.66%2.96M | -6.98%2.4M | 10.71%10.89M | 2.24%2.74M | 0.83%2.79M | 14.41%2.78M |
Deferred tax | 68.47%-1.51M | -144.60%-6.52M | 4.33%-5.84M | -4,747.69%-3.02M | 130.29%7.12M | -1,827.80%-4.79M | 83.18%-2.67M | -21.95%-6.1M | 101.64%65K | 412.11%3.09M |
Change In working capital | -55.48%18.56M | 310.56%46.75M | -15,091.35%-15.8M | 137.70%13.62M | -78.42%7.24M | 195.93%41.69M | 194.20%11.39M | 99.22%-104K | -1.94%-36.13M | 275.25%33.54M |
-Change in receivables | 21.51%-15.81M | -149.05%-1.7M | -35.88%17.23M | 36.91%29.94M | 16.62%-28.73M | -86.35%-20.14M | -92.27%3.47M | -14.23%26.88M | -39.05%21.87M | -177.37%-34.46M |
-Change in prepaid assets | -852.73%-2.96M | 340.78%3.04M | -60.67%1.06M | 103.16%137K | -47.37%2.15M | 91.64%-311K | -176.45%-1.26M | -41.93%2.7M | 17.29%-4.33M | 135.00%4.09M |
-Change in payables and accrued expense | 70.87%25.46M | -89.14%245K | -13.51%-22.73M | 21.95%-15.01M | -23.85%23.08M | 33.06%14.9M | 108.11%2.26M | 42.04%-20.02M | 20.15%-19.23M | 103.71%30.31M |
-Change in other working capital | -74.87%11.87M | 552.75%45.16M | -17.66%-11.37M | 95.82%-1.44M | -68.06%10.73M | 171.19%47.24M | 122.43%6.92M | 34.84%-9.66M | 18.00%-34.43M | 243.96%33.59M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -34.32%39.84M | -8.42%191.51M | -57.95%13.71M | 105.83%46M | -27.42%71.15M | 8.03%60.65M | -0.67%209.13M | 40.52%32.62M | 1.46%22.35M | 82.23%98.02M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -171.63%-14.25M | -44.19%-19.47M | -197.99%-6.51M | -91.00%-2.59M | 37.36%-5.12M | -194.33%-5.25M | 39.88%-13.5M | 38.81%-2.19M | 87.46%-1.36M | -141.08%-8.18M |
Capital expenditure reported | -291.30%-450K | 46.41%-1.39M | 66.11%-225K | 12.65%-656K | 66.58%-394K | ---115K | ---2.59M | ---664K | ---751K | ---1.18M |
Net PPE purchase and sale | -92.97%-2.55M | -20.88%-6.48M | -77.35%-2.08M | -115.26%-1.64M | 27.59%-1.45M | 7.61%-1.32M | 55.50%-5.36M | 58.64%-1.17M | 33.62%-760K | 41.03%-2M |
Net business purchase and sale | -195.35%-11.24M | -109.11%-11.6M | -1,099.72%-4.21M | -292.26%-298K | 34.38%-3.28M | -987.71%-3.81M | 46.72%-5.55M | 52.70%-351K | 101.60%155K | ---5M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -171.63%-14.25M | -44.19%-19.47M | -197.99%-6.51M | -91.00%-2.59M | 37.36%-5.12M | -194.33%-5.25M | 39.88%-13.5M | 38.81%-2.19M | 87.46%-1.36M | -141.08%-8.18M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 69.90%-12.28M | 7.45%-170.38M | 3.73%-32.01M | 30.04%-41.91M | -1.68%-55.65M | -12.72%-40.81M | 9.99%-184.09M | 30.94%-33.25M | 8.07%-59.91M | 1.33%-54.73M |
Net common stock issuance | 84.92%-4.98M | 12.10%-141.12M | 4.19%-24.84M | 37.36%-35.02M | 1.18%-48.23M | -10.42%-33.03M | 10.54%-160.55M | 34.92%-25.93M | 6.55%-55.9M | 2.11%-48.81M |
Cash dividends paid | -0.22%-7.6M | -5.54%-30.1M | 0.07%-7.54M | 0.40%-7.49M | -9.12%-7.49M | -14.99%-7.59M | -13.04%-28.52M | -12.67%-7.54M | -10.69%-7.52M | -16.64%-6.86M |
Proceeds from stock option exercised by employees | -69.29%300K | -59.60%2.01M | 68.04%368K | -83.12%592K | -92.07%75K | 218.24%977K | 713.73%4.98M | 113.61%219K | 143.44%3.51M | 235.46%946K |
Net other financing activities | ---- | ---1.17M | --0 | --0 | --0 | ---1.17M | ---- | ---- | ---- | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 69.90%-12.28M | 7.45%-170.38M | 3.73%-32.01M | 30.04%-41.91M | -1.68%-55.65M | -12.72%-40.81M | 9.99%-184.09M | 30.94%-33.25M | 8.07%-59.91M | 1.33%-54.73M |
Net cash flow | ||||||||||
Beginning cash position | -0.77%168.59M | 6.59%169.89M | 12.40%195.74M | -9.26%193.52M | 3.24%183.9M | 6.59%169.89M | -9.40%159.38M | -6.97%174.14M | -11.42%213.27M | -27.89%178.13M |
Current changes in cash | -8.86%13.31M | -85.55%1.67M | -780.82%-24.8M | 103.85%1.5M | -70.46%10.37M | -19.59%14.6M | 170.19%11.54M | 90.12%-2.82M | 27.87%-38.92M | 792.86%35.11M |
Effect of exchange rate changes | 155.86%329K | -7,721.05%-2.97M | -432.43%-2.35M | 432.72%722K | -3,011.54%-757K | -199.16%-589K | 56.32%-38K | -164.47%-441K | -158.65%-217K | 102.20%26K |
End cash Position | -0.91%182.22M | -1.34%168.59M | -1.34%168.59M | 12.40%195.74M | -9.26%193.52M | 3.24%183.9M | 7.22%170.88M | 7.22%170.88M | -6.97%174.14M | -11.42%213.27M |
Free cash flow | -37.80%36.84M | -8.72%183.64M | -62.92%11.41M | 109.76%43.71M | -26.93%69.3M | 8.23%59.22M | 1.36%201.17M | 51.02%30.78M | -0.21%20.84M | 88.19%94.84M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |